Ardelyx has developed a platform enabling discovery of new biological mechanisms to develop potent and efficacious therapies that minimize side effects and drug-drug interactions. The company expects IBSRELA to achieve $1 billion in annual revenue in 2029, with further growth thereafter. It partners with pharmaceutical entities in Canada, China, and Japan for international expansion.
Cyborg Score Rationale
Ardelyx reported full-year 2025 revenue of $407.32 million, up from $333.62 million, with net loss widening to $61.6 million. Full-year 2026 IBSRELA revenue is expected to be between $410 and $430 million, representing growth of at least 50%. While the company shows strong commercial execution and clear $1B revenue potential, it remains unprofitable with concentration risk in two products.
Top Insights
IBSRELA delivered significant revenue growth of 73% over 2024, and the company successfully protected patient access to XPHOZAH.
Ardelyx highlighted new patents extending protection to 2042 and ongoing late-stage development efforts reinforcing longer-term product and revenue outlook.
The company announced a multi-year partnership with the LPGA to educate and mobilize women in health, supporting women's digestive health conditions such as IBS and constipation.
The company's stock price grew approximately 18% in 2025 and is currently up 15% in 2026 YTD.
Named Competitors
Linaclotide — GI therapy for IBS-C and CIC
Phosphate Binder Therapies — Standard management for hyperphosphatemia in CKD
Emerging GI Therapeutics — Competitive landscape in constipation management
Recent Developments
Feb 2026: Announced multi-year partnership with Ladies Professional Golf Association (LPGA)
Feb 2026: Reported full-year 2025 revenue of $407.32 million with 2026 guidance of $410-430 million for IBSRELA and $110-120 million for XPHOZAH
Jan 2026: Commenced Phase 3 program for IBSRELA in chronic idiopathic constipation and began development of next-generation NHE3 inhibitor RDX10531
Open the full interactive Ardelyx, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.